Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 9:148:e140.
doi: 10.1017/S0950268820001569.

Bacillus Calmette-Guérin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study

C-H Weng  1   2 , A Saal  2 , W W-W Butt  2 , N Bica  2 , J Q Fisher  2 , J Tao  3 , P A Chan  3
Affiliations

Bacillus Calmette-Guérin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study

C-H Weng et al. Epidemiol Infect. .

Abstract

Coronavirus disease 2019 (COVID-19) has resulted in a global pandemic, and there is limited data on effective therapies. Bacillus Calmette-Guérin (BCG) vaccine, a live-attenuated strain derived from an isolate of Mycobacterium bovis and originally designed to prevent tuberculosis, has shown some efficacy against infection with unrelated pathogens. In this study, we reviewed 120 consecutive adult patients (≥18 years old) with COVID-19 at a major federally qualified health centre in Rhode Island, United States from 19 March to 29 April 2020. Median age was 39.5 years (interquartile range, 27.0-50.0), 30% were male and 87.5% were Latino/Hispanics. Eighty-two (68.3%) patients had BCG vaccination. Individuals with BCG vaccination were less likely to require hospital admission during the disease course (3.7% vs. 15.8%, P = 0.019). This association remained unchanged after adjusting for demographics and comorbidities (P = 0.017) using multivariate regression analysis. The finding from our study suggests the potential of BCG in preventing more severe COVID-19.

Keywords: Adult; BCG vaccine; COVID-19.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Moorlag S et al. (2019) Non-specific effects of BCG vaccine on viral infections. Clinical Microbiology and Infection 25, 1473–1478. - PubMed
    1. Ozdemir C et al. (2020) Is BCG vaccination effecting the spread and severity of COVID-19? Allergy. - PubMed
    1. Guan WJ et al. (2020) Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine 382, 1708–1720. - PMC - PubMed
    1. Chow EJ et al. (2020) Symptom screening at illness onset of health care personnel with SARS-CoV-2 infection in King County, Washington. JAMA. - PMC - PubMed
    1. Petrilli CM et al. (2020) Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York city: prospective cohort study. British Medical Journal 369, m1966. - PMC - PubMed